HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Abscopal effects of radiation therapy: a clinical review for the radiobiologist.

  2015cited by this paper
• Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model

  2015cited by this paper
• Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.

  2015cited by this paper
• Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

  2015cited by this paper
• Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.

  2014influential reference
• High‐mobility group box‐1 and its role in angiogenesis

  2014cited by this paper
• Malignant Mesothelioma: Development to Therapy

  2014cited by this paper
• The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics

  2014cited by this paper
• Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer

  2014cited by this paper
• Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.

  2014cited by this paper
• [Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].

  2014cited by this paper
• A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma

  2014cited by this paper
• Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

  2014cited by this paper
• Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma

  2014cited by this paper
• Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

  2013cited by this paper
• Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

  2013cited by this paper
• Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

  2013cited by this paper
• Necroptosis: the release of damage-associated molecular patterns and its physiological relevance.

  2013cited by this paper
• Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

  2013cited by this paper
• New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

  2013cited by this paper
• Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

  2013cited by this paper
• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

  2013cited by this paper
• Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

  2013cited by this paper
• Radiation therapy and immunotherapy: implications for a combined cancer treatment.

  2013cited by this paper
• Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.

  2012cited by this paper
• Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.

  2012cited by this paper
• Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.

  2012cited by this paper
• Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment

  2012cited by this paper
• A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

  2012cited by this paper
• HMGB1 promotes drug resistance in osteosarcoma.

  2012cited by this paper
• NLRP3 promotes inflammation‐induced skin cancer but is dispensable for asbestos‐induced mesothelioma

  2012cited by this paper
• Immunogenic cell death and DAMPs in cancer therapy

  2012cited by this paper
• p53/HMGB1 complexes regulate autophagy and apoptosis.

  2012cited by this paper
• Novel therapies in phase II and III trials for malignant pleural mesothelioma.

  2012cited by this paper
• Cancer immunotherapy

  2012cited by this paper
• Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells

  2011cited by this paper
• Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity.

  2011cited by this paper
• Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

  2011cited by this paper
• Pathohistological diagnosis and differential diagnosis.

  2011cited by this paper
• Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

  2011cited by this paper
• A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

  2011cited by this paper
• Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

  2011cited by this paper
• Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Endogenous HMGB1 regulates autophagy

  2010cited by this paper
• Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

  2010cited by this paper
• Antibody-based vascular tumor targeting.

  2010cited by this paper
• gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells.

  2010cited by this paper
• Cross-priming in health and disease

  2010cited by this paper
• Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation

  2010cited by this paper
• Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

  2010cited by this paper
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• The redox protein HMGB1 regulates cell death and survival in cancer treatment

  2010cited by this paper
• [Antibody therapy in cancer].

  2010cited by this paper
• HMGB1 Release and Redox Regulates Autophagy and Apoptosis in Cancer Cells

  2010cited by this paper
• Antibody–drug conjugates for cancer: poised to deliver?

  2010cited by this paper
• Cancer incidence and risk factors after solid organ transplantation

  2009cited by this paper
• The Effect of High Mobility Group Box-1 Protein on Splenic Dendritic Cell Maturation in Rats

  2009cited by this paper
• Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

  2009cited by this paper
• Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.

  2009cited by this paper
• Chemotherapy induces ATP release from tumor cells

  2009cited by this paper
• Spontaneous regression of natural killer cell lymphoma

  2009cited by this paper
• Current constructs and targets in clinical development for antibody-based cancer therapy.

  2009cited by this paper
• The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

  2009cited by this paper
• Immunological and inflammatory functions of the interleukin-1 family.

  2009cited by this paper
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

  2009cited by this paper
• Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

  2009cited by this paper
• No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.

  2009cited by this paper
• Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance

  2009cited by this paper
• Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

  2009cited by this paper
• Mesothelioma: Do asbestos and carbon nanotubes pose the same health risk?

  2009cited by this paper
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

  2009cited by this paper
• The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer.

  2009cited by this paper
• Abscopal effect in a patient with chronic lymphocytic leukemia during radiation therapy: a case report

  2009cited by this paper
• Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

  2009cited by this paper
• Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

  2009cited by this paper
• Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.

  2009cited by this paper
• Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

  2008cited by this paper
• Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.

  2008cited by this paper
• Molecular characteristics of immunogenic cancer cell death

  2008cited by this paper
• Tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer

  2008cited by this paper
• Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry

  2008cited by this paper
• Overexpression of High Mobility Group (HMG) B1 and B2 Proteins Directly Correlates with the Progression of Squamous Cell Carcinoma in Skin

  2008cited by this paper
• Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

  2008cited by this paper
• Trimodality Treatment of Malignant Pleural Mesothelioma

  2008cited by this paper
• Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1.

  2008cited by this paper
• Journal of Occupational Medicine and Toxicology Gemcitabine Combined with Oxaliplatin in Pretreated Patients with Malignant Pleural Mesothelioma: an Observational Study

  2008cited by this paper
• Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma

  2008cited by this paper
• Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

  2008cited by this paper
• HMGB1: a two-headed signal regulating tumor progression and immunity.

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Immune‐mediated dormancy: an equilibrium with cancer

  2008cited by this paper
• Pathology of mesothelioma

  2008influential reference
• Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1

  2008cited by this paper
• Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than Calretinin

  2008cited by this paper

• No citing papers are available for this paper.